Stigma feelings and quality of life in men with low testosterone
Compares stigma and illness views in men with hypogonadism and other endocrine diseases.
Plain-language title generated from the registry record
Registry title: Anticipated Stigma, Illness Identity, and Quality of Life in Male Hypogonadism
Key facts
- Where
- Bingoel and Malatya, TürkiyeSee the 2 sites
Where in Türkiye
- Bingöl University Faculty of Physical Therapy and RehabilitationBingoel, TürkiyeTaking people
- Malatya Training and Research HospitalMalatya, TürkiyeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hacettepe University
- Trial code
- NCT07752511
- Record updated
- 6 November 2026
- Original description
This study aims to systematically compare the levels of anticipated illness stigma and illness identity among men diagnosed with hypogonadism to those of men with other chronic endocrine conditions (e.g., diabetes mellitus, hypothyroidism, and hypertension). Furthermore, it examines whether these psychosocial variables predict quality-of-life deterioration specifically within the hypogonadism cohort.Read full original descriptionShow less
The Impact of Anticipated Illness Stigma and Illness Identity on Quality of Life in Men With Hypogonadism: A Comparative Study With Other Chronic Endocrine Diseases
This study aims to systematically compare the levels of anticipated illness stigma and illness identity among men diagnosed with hypogonadism to those of men with other chronic endocrine conditions (e.g., diabetes mellitus, hypothyroidism, and hypertension). Furthermore, it examines whether these psychosocial variables predict quality-of-life deterioration specifically within the hypogonadism cohort.
Inclusion: Cases:; Male, aged 18 years or older; Biochemically confirmed hypogonadism (total testosterone < 300 ng/dL with at least one clinical symptom); Regular follow-up at the endocrinology outpatient clinic; Fluent in reading and understanding Turkish; Signed informed consent; Controls:; Male, aged 18 years or older; Diagnosed with diabetes, hypertension, or hypothyroidism under regular endocrinology follow-up; Total testosterone ≥ 300 ng/dL; Age-matched to a participant in the case group (±5 years); Fluent in reading and understanding Turkish; Signed informed consent.
Exclusion: Active psychiatric diagnosis (e.g., active psychosis, bipolar disorder); Chronic inflammatory or rheumatological diseases affecting body composition (e.g., chronic kidney disease, IBD, rheumatoid arthritis, SLE, ankylosing spondylitis); Cognitive impairment or dementia precluding questionnaire completion; Klinefelter syndrome; Uncontrolled co-existing endocrine conditions or severe complications (e.g., HbA1c > 8.0%, diabetic neuropathy/nephropathy/retinopathy, non-euthyroid state); Literacy limitations preventing completion of self-report measures; Additional control exclusion: Diagnosis or clinical suspicion of hypogonadism.